1025 related articles for article (PubMed ID: 32599589)
1. Weathering the Cytokine Storm in COVID-19: Therapeutic Implications.
Iannaccone G; Scacciavillani R; Del Buono MG; Camilli M; Ronco C; Lavie CJ; Abbate A; Crea F; Massetti M; Aspromonte N
Cardiorenal Med; 2020; 10(5):277-287. PubMed ID: 32599589
[TBL] [Abstract][Full Text] [Related]
2. Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19.
Tanner T; Wahezi DM
Paediatr Respir Rev; 2020 Sep; 35():81-87. PubMed ID: 32792288
[TBL] [Abstract][Full Text] [Related]
3. Current status of potential therapeutic candidates for the COVID-19 crisis.
Zhang J; Xie B; Hashimoto K
Brain Behav Immun; 2020 Jul; 87():59-73. PubMed ID: 32334062
[TBL] [Abstract][Full Text] [Related]
4. Cytokine Storm in COVID-19: "When You Come Out of the Storm, You Won't Be the Same Person Who Walked in".
Castelli V; Cimini A; Ferri C
Front Immunol; 2020; 11():2132. PubMed ID: 32983172
[TBL] [Abstract][Full Text] [Related]
5. [Advances in the research of mechanism and related immunotherapy on the cytokine storm induced by coronavirus disease 2019].
Chen C; Zhang XR; Ju ZY; He WF
Zhonghua Shao Shang Za Zhi; 2020 Jun; 36(6):471-475. PubMed ID: 32114747
[TBL] [Abstract][Full Text] [Related]
6. Potential strategies for combating COVID-19.
Shamim S; Khan M; Kharaba ZJ; Ijaz M; Murtaza G
Arch Virol; 2020 Nov; 165(11):2419-2438. PubMed ID: 32778950
[TBL] [Abstract][Full Text] [Related]
7. Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials.
Abrams-Downey A; Saabiye J; Vidaurrazaga M
Eur Urol Focus; 2020 Sep; 6(5):1028-1031. PubMed ID: 32563675
[No Abstract] [Full Text] [Related]
8. Therapeutic options for the management of severe COVID-19: A rheumatology perspective.
Mendoza-Pinto C; García-Carrasco M; Munguía Realpozo P; Méndez-Martínez S
Reumatol Clin (Engl Ed); 2021 Oct; 17(8):431-436. PubMed ID: 34625144
[TBL] [Abstract][Full Text] [Related]
9. The COVID-19 Cytokine Storm; What We Know So Far.
Ragab D; Salah Eldin H; Taeimah M; Khattab R; Salem R
Front Immunol; 2020; 11():1446. PubMed ID: 32612617
[TBL] [Abstract][Full Text] [Related]
10. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
[TBL] [Abstract][Full Text] [Related]
11. Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients.
Cala-García JD; Sierra-Bretón JD; Cavelier-Baiz JE; Faccini-Martínez ÁA; Pérez-Díaz CE
Immunotherapy; 2020 Oct; 12(15):1127-1132. PubMed ID: 32664810
[No Abstract] [Full Text] [Related]
12. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Atluri S; Manchikanti L; Hirsch JA
Pain Physician; 2020 Mar; 23(2):E71-E83. PubMed ID: 32214286
[TBL] [Abstract][Full Text] [Related]
13. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies.
Tang Y; Liu J; Zhang D; Xu Z; Ji J; Wen C
Front Immunol; 2020; 11():1708. PubMed ID: 32754163
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics.
Qin H; Zhao A
Protein Cell; 2020 Oct; 11(10):707-722. PubMed ID: 32519302
[TBL] [Abstract][Full Text] [Related]
15. COVID-19: Cytokine storm modulation/blockade with oral polyvalent immunoglobulins (PVIG, KMP01D): A potential and safe therapeutic agent (
Sly LM; Braun P; Woodcock BG
Int J Clin Pharmacol Ther; 2020 Dec; 58(12):678-686. PubMed ID: 33141018
[TBL] [Abstract][Full Text] [Related]
16. Extracorporeal Hemoadsorption: An Option for COVID-19-Associated Cytokine Storm Syndrome.
Napp LC; Bauersachs J
Shock; 2020 Nov; 54(5):700-701. PubMed ID: 32453251
[No Abstract] [Full Text] [Related]
17. Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper.
Bhaskar S; Sinha A; Banach M; Mittoo S; Weissert R; Kass JS; Rajagopal S; Pai AR; Kutty S
Front Immunol; 2020; 11():1648. PubMed ID: 32754159
[TBL] [Abstract][Full Text] [Related]
18. Novel therapeutic approaches for treatment of COVID-19.
Hossein-Khannazer N; Shokoohian B; Shpichka A; Aghdaei HA; Timashev P; Vosough M
J Mol Med (Berl); 2020 Jun; 98(6):789-803. PubMed ID: 32494931
[TBL] [Abstract][Full Text] [Related]
19. Cytokine Storm in COVID-19 Patients, Its Impact on Organs and Potential Treatment by QTY Code-Designed Detergent-Free Chemokine Receptors.
Mustafa MI; Abdelmoneim AH; Mahmoud EM; Makhawi AM
Mediators Inflamm; 2020; 2020():8198963. PubMed ID: 33029105
[TBL] [Abstract][Full Text] [Related]
20. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome.
Chen LYC; Hoiland RL; Stukas S; Wellington CL; Sekhon MS
Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32883678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
